Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: united therapeutic’s

FDA OKs United Therapeutics’ cancer drug (access required)

United Therapeutics, of Silver Spring, has received Food and Drug Administration approval for its cancer drug Unituxin, the company announced Tuesday. Unituxin treats the rare pediatric cancer neuroblastoma. Roger Jeffs, Ph.D., United Therapeutics’ president and co-chief executive officer, said in ...

Read More »

United Therapeutics profit soars (access required)

United Therapeutics, of Silver Spring, a biotechnology company, nearly doubled its profit for 2014, boosted by a strong fourth quarter. United Therapeutics reported net income of $340.1 million, or $6.28 per diluted share, for the year, compared with $174.6 million ...

Read More »

United Therapeutics reaches deal for Remodulin system (access required)

United Therapeutics Corp., a Silver Spring-based biotechnology company, announced it has signed an agreement with DEKA Research & Development Corp. for the development of a subcutaneous delivery of United Therapeutics’ Remodulin injection via a pre-filled, semi-disposable pump system. Remodulin is ...

Read More »

United Therapeutics posts loss

United Therapeutics Corp., a Silver Spring-based biotechnology company, reported a net loss of $25.2 million, or 53 cents per share, for the quarter ended Sept. 30. In the same quarter of 2013, United Therapeutics posted net income of $62.7 million, ...

Read More »

United Therapeutics up in last quarter

United Therapeutics Corp., of Silver Spring, a biotechnology company that develops products to address chronic and life-threatening conditions, reported increases in profit and revenue for the quarter ended June 30. Net income was $111.9 million, or $2.35 per share, compared ...

Read More »

United Therapeutics’ earnings soar (access required)

United Therapeutics Corp., of Silver Spring, a specialty drug maker that develops and markets treatments for unmet medical needs of patients with chronic and life-threatening conditions, reported first-quarter net income totaled $137.5 million, or $2.43 per diluted share, an increase of more than 120 percent compared to the $62.3 million, or $1.19 per diluted share, reported in the prior-year period.

Read More »

FDA deals setback to Silver Spring-based United Therapeutics (access required)

United Therapeutics Corp., of Silver Spring, received a setback from the Food and Drug Administration when federal regulators, for the second time, rejected the biopharmaceutical company’s new drug application for oral treprostinil, a treatment for pulmonary arterial hypertension, which is high blood pressure in the arteries that supply the lungs.

Read More »

Silver Spring-based United Therapeutics’ Q4 profit surges

United Therapeutics’ fourth-quarter earnings nearly doubled with more people getting prescriptions for its cardiopulmonary drugs. Net income for the Silver Spring-based drug company totaled $83.3 million, or $1.60 per share, compared to $43.2 million, or 77 cents per share, in ...

Read More »